11 Jul 2008 10:51
11th July 2008
REGEN THERAPEUTICS PLC
("ReGen" or the "Company"; Ticker: (RGT))
TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):
ReGen Therapeutics Plc
2. Reason for the notification:
An acquisition or disposal of voting rights
3. Full name of person(s) subject to the notification obligation (iii):
Andrew Clement Wilson
4. Full name of shareholder(s) (if difference from 3):
As above
5. Date of the transaction and date on which the threshold is crossed or reached (v):
9 July 2008
6. Date on which issued notified:
10 July 2008
7. Threshold(s) that is/are crossed or reached:
14%
8. Notified details
A: Voting rights attached to shares
Class/type of share if possible using the ISIN Code GB00B28XMY25
Situation Previous to the triggering transaction (vi) -
Number of Shares 1,490,000
Number of Voting Rights (viii) 1,490,000
Resulting situation after the triggering transaction (viii) -
Number of Shares 1,616,000
Number of Voting Rights - Direct (x) 1,616,000
Number of Voting Rights - Indirect (xi) N/A
% of voting rights - Direct 14.07%
% of voting rights - Indirect N/A
B: Financial Instruments
Resulting situation after the triggering transaction (xii)
Type of financial instrument N/A
Expiration date (xiii) N/A
Exercise/Conversion Period/Date (xiv) N/A
Number of voting rights that may be acquired if the
instrument is exercised/converted N/A
% of voting rights N/A
Total (A+B)
Number of voting rights 1,616,000
% of voting rights 14.07
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):
Shares are held in own name
Proxy Voting:
10. Name of the proxy holder: N/A
11. Number of voting rights proxy holder will cease to hold: N/A
12. Date on which proxy holder will cease to hold voting rights: N/A
13. Additional information: N/A
14. Contact name: N/A
15. Contact telephone number: N/A
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel: +44 (0) 207 153 4920
Roland Cornish / Felicity Geidt
Beaumont Cornish Limited
Tel: +44(0) 207 628 3396